Phase 2 N=24 Randomized Quadruple-blind Treatment

D-cycloserine Adjunctive Treatment for Posttraumatic Stress Disorder (PTSD) in Adolescents

Posttraumatic Stress Disorder · PTSD

Bottom Line

View on ClinicalTrials.gov: NCT01157429 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2017

Primary outcome: Primary: Child PTSD Symptom Scale (CPSS) — 20.4; 11.0 units on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: D-cycloserine (Drug); Placebo pill (Drug); CBT (Behavioral)
Age: Pediatric, Adult · 13+ yrs
Sex: All
Sponsor: Tulane University School of Medicine
Primary completion: Jun 2012

Outcome Measures

Outcome	Result	p-value
PRIMARY Child PTSD Symptom Scale (CPSS)	20.4; 11.0	—

Summary

The purpose of this study is to show whether D-cycloserine in combination with cognitive behavioral therapy (CBT) is more effective than CBT plus placebo to reduce symptoms of posttraumatic stress disorder (PTSD) in 13-18 year-old children.

Eligibility Criteria

Inclusion Criteria

Certain number of PTSD symptoms plus functional impairment
Must be able to swallow pills

Exclusion Criteria

Serious kidney or liver disease
Epilepsy
Bipolar disorder
Psychosis

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01157429). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.